These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

566 related articles for article (PubMed ID: 27124925)

  • 21. [Analysis of CALR, JAK2 and MPL gene mutations in BCR-ABL negative myeloproliferative neoplasms].
    Ouyang Y; Qiao C; Wang J; Xiao L; Zhang S
    Zhonghua Yi Xue Za Zhi; 2015 May; 95(18):1369-73. PubMed ID: 26178351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High resolution melting analysis: a rapid and accurate method to detect CALR mutations.
    Bilbao-Sieyro C; Santana G; Moreno M; Torres L; Santana-Lopez G; Rodriguez-Medina C; Perera M; Bellosillo B; de la Iglesia S; Molero T; Gomez-Casares MT
    PLoS One; 2014; 9(7):e103511. PubMed ID: 25068507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of CALR mutants causes mpl-dependent thrombocytosis in zebrafish.
    Lim KH; Chang YC; Chiang YH; Lin HC; Chang CY; Lin CS; Huang L; Wang WT; Gon-Shen Chen C; Chou WC; Kuo YY
    Blood Cancer J; 2016 Oct; 6(10):e481. PubMed ID: 27716741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
    Ojeda MJ; Bragós IM; Calvo KL; Williams GM; Carbonell MM; Pratti AF
    Hematology; 2018 May; 23(4):208-211. PubMed ID: 28990497
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.
    Nangalia J; Massie CE; Baxter EJ; Nice FL; Gundem G; Wedge DC; Avezov E; Li J; Kollmann K; Kent DG; Aziz A; Godfrey AL; Hinton J; Martincorena I; Van Loo P; Jones AV; Guglielmelli P; Tarpey P; Harding HP; Fitzpatrick JD; Goudie CT; Ortmann CA; Loughran SJ; Raine K; Jones DR; Butler AP; Teague JW; O'Meara S; McLaren S; Bianchi M; Silber Y; Dimitropoulou D; Bloxham D; Mudie L; Maddison M; Robinson B; Keohane C; Maclean C; Hill K; Orchard K; Tauro S; Du MQ; Greaves M; Bowen D; Huntly BJP; Harrison CN; Cross NCP; Ron D; Vannucchi AM; Papaemmanuil E; Campbell PJ; Green AR
    N Engl J Med; 2013 Dec; 369(25):2391-2405. PubMed ID: 24325359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms.
    Trung NT; Quyen DT; Hoan NX; Giang DP; Trang TTH; Velavan TP; Bang MH; Song LH
    BMC Med Genet; 2019 Jun; 20(1):115. PubMed ID: 31248375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms.
    Pietra D; Rumi E; Ferretti VV; Di Buduo CA; Milanesi C; Cavalloni C; Sant'Antonio E; Abbonante V; Moccia F; Casetti IC; Bellini M; Renna MC; Roncoroni E; Fugazza E; Astori C; Boveri E; Rosti V; Barosi G; Balduini A; Cazzola M
    Leukemia; 2016 Feb; 30(2):431-8. PubMed ID: 26449662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms.
    Tefferi A; Thiele J; Vannucchi AM; Barbui T
    Leukemia; 2014 Jul; 28(7):1407-13. PubMed ID: 24441292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [New disease markers within the chronic myeloproliferative neoplasms].
    Holmström MO; Ocias LF; Kallenbach K; Kjær L; Kristensen TK; Pallisgaard N; Petersen BL; Skov V; de Stricker K; Larsen TS; Hasselbalch HC
    Ugeskr Laeger; 2015 May; 177(19):. PubMed ID: 25967091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations.
    Andrikovics H; Krahling T; Balassa K; Halm G; Bors A; Koszarska M; Batai A; Dolgos J; Csomor J; Egyed M; Sipos A; Remenyi P; Tordai A; Masszi T
    Haematologica; 2014 Jul; 99(7):1184-90. PubMed ID: 24895336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Different Shapes Of Megakaryocytes In Essential Thrombocythemia.
    Faraz M; Mansoori H; Ali M; Ali SA
    J Ayub Med Coll Abbottabad; 2022; 34(2):389-391. PubMed ID: 35576311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value.
    Vannucchi AM; Rotunno G; Bartalucci N; Raugei G; Carrai V; Balliu M; Mannarelli C; Pacilli A; Calabresi L; Fjerza R; Pieri L; Bosi A; Manfredini R; Guglielmelli P
    Leukemia; 2014 Sep; 28(9):1811-8. PubMed ID: 24618731
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Mutation Profile of Calreticulin in Patients with Myeloproliferative Neoplasms and Acute Leukemia.
    Wang J; Hao J; He N; Ji C; Ma D
    Turk J Haematol; 2016 Sep; 33(3):180-6. PubMed ID: 26377485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CAL2 Immunohistochemical Staining Accurately Identifies CALR Mutations in Myeloproliferative Neoplasms.
    Nomani L; Bodo J; Zhao X; Durkin L; Loghavi S; Hsi ED
    Am J Clin Pathol; 2016 Oct; 146(4):431-8. PubMed ID: 27686170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms.
    Di Buduo CA; Abbonante V; Marty C; Moccia F; Rumi E; Pietra D; Soprano PM; Lim D; Cattaneo D; Iurlo A; Gianelli U; Barosi G; Rosti V; Plo I; Cazzola M; Balduini A
    Blood; 2020 Jan; 135(2):133-144. PubMed ID: 31697806
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms.
    Mózes R; Gángó A; Sulák A; Vida L; Reiniger L; Timár B; Krenács T; Alizadeh H; Masszi T; Gaál-Weisinger J; Demeter J; Csomor J; Matolcsy A; Kajtár B; Bödör C
    Pathology; 2019 Apr; 51(3):301-307. PubMed ID: 30606612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Megakaryocytes, erythropoietic and granulopoietic cells express CAL2 antibody in myeloproliferative neoplasms carrying CALR gene mutations.
    Ali H; Puccio I; Akarca AU; Bob R; Pomplun S; Keong Wong W; Gupta R; Sekhar M; Lambert J; Al-Masri H; Stein H; Marafioti T
    Int J Exp Pathol; 2021 Feb; 102(1):45-50. PubMed ID: 32929772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CALR mutation characterization in myeloproliferative neoplasms.
    Bilbao-Sieyro C; Florido Y; Gómez-Casares MT
    Oncotarget; 2016 Aug; 7(33):52614-52617. PubMed ID: 27384487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018.
    Mejía-Ochoa M; Acevedo Toro PA; Cardona-Arias JA
    BMC Cancer; 2019 Jun; 19(1):590. PubMed ID: 31208359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia.
    Kang MG; Choi HW; Lee JH; Choi YJ; Choi HJ; Shin JH; Suh SP; Szardenings M; Kim HR; Shin MG
    Oncotarget; 2016 Aug; 7(35):57036-57049. PubMed ID: 27486987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.